XBiotech Inc.

Listed Company

XBITCIK 0001626878NasdaqNon-AcceleratedSmaller ReportingPharmaceutical PreparationsA1CAFY ends Dec 31

Period

FY 2025

Revenue

—

Net Income

$-45.54M

Total Assets

—

Equity

—

Shares Out

30.49M

Op. Cash Flow

$-39.92M

XBIT$2.31−28.26% · past yearDBEQ Basic

Daily closing prices

Business

XBiotech Inc. is a biopharmaceutical company that discovers and develops True Human™ monoclonal antibodies derived from natural human immune responses for treating inflammatory, infectious, and oncologic diseases. The company's pipeline includes anti-interleukin-1 alpha (IL-1a) therapies in clinical development for oncology, rheumatology, and neurology, along with infectious-disease candidates targeting MRSA, C. difficile, shingles, and influenza. XBiotech operates an integrated research, manufacturing, and clinical development center in Austin, Texas, and previously generated revenue through contract manufacturing and clinical trial services.

Summary from 10-K filed 2026-03-13

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Research and development	47	38	33	32	28
General and administrative	8	5	5	6	9
Total operating expenses	—	42	38	38	38
Loss from operations	−56	−42	−38	−34	−25
Interest income	6	10	10	4	467,000
Interest expense	−88,000	−807,000	0	—	—
Other expense	1	432,000	883,000	−121,000	−132,000
Foreign exchange gain (loss)	3	−6	2	−3	−711,000
Total other income	10	4	13	902,000	−376,000
Income before income taxes	−45	−39	−24	−34	−25
Income tax (expense) benefit	−235,000	32,000	−244,000	688,000	8
Net loss	−46	−39	−25	−33	−17
Net loss per sharebasic and diluted (in dollars per share)	−1.49	−1.26	−0.81	−1.08	−0.58
Shares used to compute basic and diluted net loss per share (in shares)	30	30	30	30	30

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Cash and cash equivalents	126	173	200	157	237
Accrued interest receivable	360,000	700,000	860,000	1	0
Income tax receivable	0	158,000	75,000	548,000	9
Prepaid expenses and other current assets	1	1	760,000	601,000	934,000
Total current assets	127	175	202	220	247
Property and equipment, net	23	25	25	26	28
Total assets	150	199	227	246	275
Accounts payable	2	2	3	2	2
Accrued expenses	6	3	4	2	1
Income tax payable	76,000	0	83,000	55,000	10,000
Total current liabilities	8	15	6	4	3
Income tax payable	2	2	2	2	1
Deferred tax liability	5,000	0	0	59,000	873,000
Total liabilities	10	17	8	6	6
Preferred stock, no par value, unlimited shares authorized, no shares outstanding	0	0	0	0	0
Common stock, no par value, unlimited shares authorized, 30,487,731 share issued and outstanding at December 31, 2025 and December 31, 2024	277	273	271	267	262
Accumulated deficit	−136	−91	−52	−28	5
Total shareholders equity	140	182	219	240	269
Total liabilities and shareholders equity	150	199	227	246	275

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31
Depreciation	2	2	2	3	3
Deferred tax liability	5,000	0	−59,000	−815,000	873,000
Foreign exchange loss	−3	6	−2	3	0
Share-based compensation expense	4	2	3	5	4
Income tax receivable	234,000	−83,000	473,000	9	−2
Accrued interest receivable	340,000	160,000	356,000	−1	0
Prepaid expenses and other current assets	−10,000	−271,000	−160,000	334,000	−352,000
Accounts payable	−688,000	−364,000	91,000	357,000	−514,000
Accrued expenses	4	−877,000	2	229,000	23,000
Long term income tax payable	78,000	−24,000	123,000	155,000	212,000
Net cash used in operating activities	−40	−31	−19	−15	69
Purchase of property and equipment	−289,000	−1	−362,000	−585,000	−4
Net cash used in investing activities	−289,000	−1	61	−64	−4
Issuance of common stock under stock option plan	—	200,000	5,000	0	8
Net cash (used in) provided by financing activities	−10	10	−9,000	0	−67
Effect of foreign exchange rate on cash and cash equivalents	3	−6	−46,000	−961,000	705,000
Net change in cash and cash equivalents	−47	−27	43	−80	−383,000
Accrued purchases of property and equipment	0	70,000	19,000	18,000	93,000
Cash paid for interest	486,000	400,000	0	—	—
Cash paid (refunded) for income taxes	−81,000	87,000	141,000	—	—

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro

Frequently asked questions

What is XBiotech Inc.'s CIK number?

XBiotech Inc.'s SEC CIK number is 0001626878 (1626878). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.

Where can I find XBiotech Inc.'s SEC filings?

All of XBiotech Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.

Look up any company's CIK number →